News and Trends 27 Jan 2023
EMA accepts Marketing Authorization Application for lecanemab to treat early Alzheimer’s disease
BioArctic AB's partner Eisai says the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab. Lecanemab,…